The use of desmopressin in von Willebrand disease: The experience of the first 30 years (1977-2007)

Haemophilia

Volumn 14, Issue SUPPL. 1, 2008, Pages 5-14

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Biological response; Clinical efficacy; Desmopressin; Inherited von Willebrand disease; von Willebrand factor; VWD types

Indexed keywords

AMINO ACID DERIVATIVE; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; EMOSINT; SODIUM CHLORIDE; SYNTHETIC PEPTIDE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; FLUSHING; HEADACHE; HEMOSTASIS; HUMAN; MAJOR SURGERY; MINOR SURGERY; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; HEMORRHAGE; HEMOSTATICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VON WILLEBRAND DISEASE;

EID: 37449014098     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01610.x     Document Type: Review

References (38)

1. Castaman G, Federici AB, Rodeghiero F, Mannnucci PM. Von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
2. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257-79.
3. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia 2002; 8: 607-21.
4. Sadler JE, Budde U, Eikenboom JCJ et al. Update on the pathophysiology and classification of von Willebrand disease. A report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
5. Federici AB. Acquired von Willebrand syndrome: An underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43: S48-58.
6. Mannucci PM. Treatment of von Willebrand disease. N Eng J Med 2004; 351: 683-94.
7. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. A new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1977; 1: 869-72.
8. Cash JD, Garder AMA, Da Costa J. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man. Br J Haematol 1974; 27: 363-64.
9. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanisms of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
10. Kaufmann JE, Oksche A, Wollllheim CB et al. Vasopressin- induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106: 107-16.
11. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 662-89.
12. Rosemberg JB, Foster PA, Kaufman RJ et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998; 101: 613-24
13. Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-61.
14. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
15. Mannucci PM, Canciani MT, Rota L, Donovam BS. Response of FVIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 1981; 47: 283-93.
16. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000.
17. Federici AB, Mazurier C, Berntorp E et al. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004; 103: 2032-8.
18. Castaman G, Lethagen S, Federici AB et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD). Results from the European study MCMDM-1VWD. Blood 2007; in press.
19. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia A and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
20. Federici AB, Castaman G, Franchini M et al. Clinical use of Haemate-P in inherited von Willebrand disease: A cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
21. Mannucci PM, Lombardi R, Bader R et al. Heterogeneity of type I von Willebrand's disease: Evidence for a subgroup with an abnormal von Willebrand Factor. Blood 1985; 66: 796-802.
22. Gralnick HR, Williams SB, McKeown LP et al. DDAVP in type IIA von Willebrand's disease. Blood 1986; 67: 465-8.
23. Holmberg L, Nilsson IM, Borge L et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease. N Engl J Med 1983; 309: 816-21.
24. Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Hemophilia 1996; 2: 73-6.
25. Castaman G, Eikenboom JCJ, Rodeghiero F, Briet E, Reitsma PH. A novel candidate mutation (Arg 611 → His) in type 1 "platelet discordant" von Willebrand's disease with desmopressin-induced thrombocytopenia. Br J Haematol 1995; 89: 656-9.
26. Mazurier C, Gaucher C, Jorieux S, Goudemand M and the collaborative group. Biological effect of desmopressin in eight patients with type 2N (Normandy) von Willebrand disease. Br J Haematol 1994; 88: 849-54.
27. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive von Willebrand disease. Br J Haematol 1995; 89: 147-51.
28. Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 2000; 84: 345-9.
29. Federici AB, Stabile F, Castaman G et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
30. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982 Jun; 59: 1272-8.
31. de la Fuente B, Kasper CK, Rickless FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
32. Nitu-Walley IC, Griffoen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 280-4.
33. Revel-Vilk S, Schmugge M, Carcao et al. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003; 25: 874-9.
34. Federici AB, Bucciarelli P, Castaman G et al. Incidence and determinants of bleeding in different types of von Willebrand disease: Results of the first prospective multicenter study on 814 Italian patients. Blood 2007; abstract 49th Annual ASH Annual Meeting.
35. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
36. Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med 1988; 318: 121.
37. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28: 63-5.
38. Olsen EHN, McCain AS, Merricks EP et al. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade release by desmopressin. Blood 2003; 102: 436-41.